Saturday, April 13, 2024
wellness India Expo
Home Tags US

Tag: US

Veeda Clinical Research acquires European CRO ‘Heads’

With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia Pacific

SynaptixBio awarded second FDA Orphan Drug Designation to boost search for...

The leading biotech company is now aiming to develop treatment for second variant of TUBB4A leukodystrophy

“There are inconstancies across biosimilar classes right now”

Thomas Newcomer, VP, Head of US Market Access, Samsung Bioepis shares insightful perspectives on the US and Indian biosimilar markets

Strong performance in US market to support growth of Indian pharma...

The projected revenue growth in FY2024 will be primarily supported by 11-13% expansion in the US market and 7-9% growth in the domestic market

Medtech startup Instashield signs MOU with Montgomery County for expansion into...

This significant agreement was made possible with the support of the US India SME Council during the Economic Development Trade Mission to India

Inflation law drives biologic drugs to outpace small molecules in venture...

According to GlobalData’s Pharma Intelligence Center Deals database, the US biotechs saw 48% or $1.1 billion more in innovator drug venture financing, reaching a total deal value of $3.2 billion in 2023

Biologic advantage: European pharma sales set to surpass US rivals by...

This transformative shift in global market dynamics is fueled by the rapid growth of biologic sales

Pricing pressures & regulatory overhang affect margins of Indian pharma companies...

Continued pricing pressures in the US and European markets and cost inflation likely to result in 50-100 bps contraction in operating profit margin for ICRA’s sample set in FY2023

Pfizer initiates Phase 3 Study of mRNA-based Influenza vaccine

First Phase 3 efficacy study to be conducted using an mRNA-based influenza vaccine; study will enroll 25,000 U.S. adults 18 years and older

Pricing pressures & regulatory scrutiny persist in US generics pharma industry:...

Some major Indian pharmaceutical companies reported sizeable impairment losses and also announced discontinuation of some products or segments due to lower earnings potential